1083 related articles for article (PubMed ID: 23200807)
1. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease.
Yan MH; Wang X; Zhu X
Free Radic Biol Med; 2013 Sep; 62():90-101. PubMed ID: 23200807
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in Alzheimer's disease cybrid cell.
Gan X; Huang S; Wu L; Wang Y; Hu G; Li G; Zhang H; Yu H; Swerdlow RH; Chen JX; Yan SS
Biochim Biophys Acta; 2014 Feb; 1842(2):220-31. PubMed ID: 24252614
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
5. Parkinson disease: from pathology to molecular disease mechanisms.
Dexter DT; Jenner P
Free Radic Biol Med; 2013 Sep; 62():132-144. PubMed ID: 23380027
[TBL] [Abstract][Full Text] [Related]
6. Impaired autophagy and APP processing in Alzheimer's disease: The potential role of Beclin 1 interactome.
Salminen A; Kaarniranta K; Kauppinen A; Ojala J; Haapasalo A; Soininen H; Hiltunen M
Prog Neurobiol; 2013; 106-107():33-54. PubMed ID: 23827971
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial diseases of the brain.
Chaturvedi RK; Flint Beal M
Free Radic Biol Med; 2013 Oct; 63():1-29. PubMed ID: 23567191
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease.
Verri M; Pastoris O; Dossena M; Aquilani R; Guerriero F; Cuzzoni G; Venturini L; Ricevuti G; Bongiorno AI
Int J Immunopathol Pharmacol; 2012; 25(2):345-53. PubMed ID: 22697066
[TBL] [Abstract][Full Text] [Related]
9. Metals, oxidative stress and neurodegenerative disorders.
Jomova K; Vondrakova D; Lawson M; Valko M
Mol Cell Biochem; 2010 Dec; 345(1-2):91-104. PubMed ID: 20730621
[TBL] [Abstract][Full Text] [Related]
10. Interplay between MicroRNAs and Oxidative Stress in Neurodegenerative Diseases.
Konovalova J; Gerasymchuk D; Parkkinen I; Chmielarz P; Domanskyi A
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801298
[TBL] [Abstract][Full Text] [Related]
11. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria and neuroplasticity.
Cheng A; Hou Y; Mattson MP
ASN Neuro; 2010 Oct; 2(5):e00045. PubMed ID: 20957078
[TBL] [Abstract][Full Text] [Related]
13. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
14. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression.
Manczak M; Anekonda TS; Henson E; Park BS; Quinn J; Reddy PH
Hum Mol Genet; 2006 May; 15(9):1437-49. PubMed ID: 16551656
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer's disease.
Manczak M; Kandimalla R; Fry D; Sesaki H; Reddy PH
Hum Mol Genet; 2016 Dec; 25(23):5148-5166. PubMed ID: 27677309
[TBL] [Abstract][Full Text] [Related]
16. Oxidative stress and altered mitochondrial protein expression in the absence of amyloid-β and tau pathology in iPSC-derived neurons from sporadic Alzheimer's disease patients.
Birnbaum JH; Wanner D; Gietl AF; Saake A; Kündig TM; Hock C; Nitsch RM; Tackenberg C
Stem Cell Res; 2018 Mar; 27():121-130. PubMed ID: 29414602
[TBL] [Abstract][Full Text] [Related]
17. Perspectives of drug-based neuroprotection targeting mitochondria.
Procaccio V; Bris C; Chao de la Barca JM; Oca F; Chevrollier A; Amati-Bonneau P; Bonneau D; Reynier P
Rev Neurol (Paris); 2014 May; 170(5):390-400. PubMed ID: 24792485
[TBL] [Abstract][Full Text] [Related]
18. A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer's Amyloid-
Li Y; Lu J; Cao X; Zhao H; Gao L; Xia P; Pei G
Oxid Med Cell Longev; 2020; 2020():7698560. PubMed ID: 32104538
[TBL] [Abstract][Full Text] [Related]
19. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases.
Mattson MP; Pedersen WA; Duan W; Culmsee C; Camandola S
Ann N Y Acad Sci; 1999; 893():154-75. PubMed ID: 10672236
[TBL] [Abstract][Full Text] [Related]
20. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice.
Aliev G; Seyidova D; Lamb BT; Obrenovich ME; Siedlak SL; Vinters HV; Friedland RP; LaManna JC; Smith MA; Perry G
Neurol Res; 2003 Sep; 25(6):665-74. PubMed ID: 14503022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
